دسترسی یکساله به بیش از ۵۰۰ ژورنال روز جهان موجود در سامانه
-
http://medilib.ir
- ﻣﺪﺕ ﺯﻣﺎﻥ : 365 ﺭﻭﺯ
قیمت : 3,800,000 تومان- قیمت ویژه : 1,900,000تومان
Potential impact of the steroid hormone, vitamin D, on the vasculature
YinTintutPhDabcLinda L.DemerMD, PhDabde
doi : 10.1016/j.ahj.2021.05.012
Volume 239, September 2021, Pages 147-153
A prospective multicenter validation study for a novel angiography-derived physiological assessment software: Rationale and design of the radiographic imaging validation and evaluation for Angio-iFR (ReVEAL iFR) study
MasafumiOnoMDabPatrick W.SerruysMD, PhDbcManesh R.PatelMDdJavierEscanedMD, PhDeTakashiAkasakaMD, PhDfMartijn A. vanLavierenMScagChristianHaasePhDgMichaelGrassPhDgNorihiroKogameMDaHironoriHaraMDabHideyukiKawashimaMDabJoanna J.WykrzykowskaMD, PhDhJan J.PiekMD, PhDaScotGargMD, PhDiNeilO'LearyPhDbBeckyInderbitzenMSEgYoshinobuOnumaMD, PhDb
doi : 10.1016/j.ahj.2021.05.004
Volume 239, September 2021, Pages 19-26
Rationale and design of the intravenous iron for treatment of anemia before cardiac surgery trial
Paul S.MylesMPH, DScabTobyRichardsBSc, MDbcAndrewKleinMBBS, FRCAbdJulianSmithMBBS, MSefErica M.WoodMBBS, FRACPghStephaneHeritierMMath, PhDhDavidMcGiffinFRACSiSilvaZavarsekPhDjJoelSymonsMBBCh, FANZCAabZoe K.McQuiltenMBBS, FRACPghRobert A.BakerPhD, CCPkKeyvanKarkoutiMSc, MDlSophiaWallaceBSc, MPHabthe ANZCA Clinical Trials Network
doi : 10.1016/j.ahj.2021.05.008
Volume 239, September 2021, Pages 64-72
Batch enrollment for an artificial intelligence-guided intervention to lower neurologic events in patients with undiagnosed atrial fibrillation: rationale and design of a digital clinical trial
XiaoxiYaoPhD12Zachi I.AttiaMS2Emma M.Behnken3KelliWalvatneMBA1Rachel E.GiblonMS4SijiaLiuPhD4Konstantinos C.SiontisMD2Bernard J.GershMB, ChB, DPhil2JonathanGraff-RadfordMD5Alejandro A.RabinsteinMD5Paul A.FriedmanMD2Peter A.NoseworthyMD2
doi : 10.1016/j.ahj.2021.05.006
Volume 239, September 2021, Pages 73-79
Study design and rationale of VALOR-HCM: evaluation of mavacamten in adults with symptomatic obstructive hypertrophic cardiomyopathy who are eligible for septal reduction therapy
Milind Y.DesaiMD, MBAabcKathyWolskiMPHbcAnjaliOwensMDdeSrihari S.NaiduMDfJeffrey B.GeskeMDgNicholas G.SmediraMD, MBAadHartzellSchaffMDhKathyLamplMDiEllenMcErleanRNbcChristinaSewellRNbcDavidZhangPhDiJay M.EdelbergMD, PhDiAmy J.SehnertMDiSteven E.NissenMDbc
doi : 10.1016/j.ahj.2021.05.007
Volume 239, September 2021, Pages 80-89
Hypertrophic cardiomyopathy (HCM) is a primary myocardial disorder which frequently leads to symptoms such as dyspnea and exercise intolerance, often due to severe dynamic left ventricular outflow tract obstruction (LVOTO). Current guideline-recommended pharmacotherapies have variable therapeutic responses to relieve LVOTO. In recent phases 2 and 3, clinical trials for symptomatic obstructive HCM (oHCM), mavacamten, a small molecule inhibitor of ?-cardiac myosin has been shown to improve symptoms, exercise capacity, health status, reduce LVOTO, along with having a beneficial impact on cardiac structure and function.
Catheter-based alcohol-mediated renal denervation for the treatment of uncontrolled hypertension: design of two sham-controlled, randomized, blinded trials in the absence (TARGET BP OFF-MED) and presence (TARGET BP I) of antihypertensive medications
FelixMahfoudMD, PhDaMichaelWeberMD, PhDbRoland E.SchmiederMD, PhDcMelvin D.LoboMD, PhDdPeter J.BlankestijnMDeAlexandrePersuMD, PhDfTim A.FischellMDgHelenPariseScDhAtulPathakMD, PhDiDavid E.KandzariMDj
doi : 10.1016/j.ahj.2021.05.015
Volume 239, September 2021, Pages 90-99
Sacubitril/valsartan versus enalapril on exercise capacity in patients with heart failure with reduced ejection fraction: A randomized, double-blind, active-controlled study
Marcelo Rodriguesdos SantosPhDaMaria-Janieire de Nazaré NunesAlvesMD, PhDaCamila Paix?oJord?oMScaCaio Eduardo NovaesPintoMScaKelly Thayane SouzaCorreaPhDaFrancis Ribeirode SouzaPhDaGuilherme Wesley Peixotoda FonsecaPhDaJoaquimTomaz FilhoBPaMarcelCostaMDaRosa Maria RodriguesPereiraMD, PhDbCarlos EduardoNegr?oPhDacAntônio Carlos PereiraBarrettoMD, PhDa
doi : 10.1016/j.ahj.2021.05.005
Volume 239, September 2021, Pages 1-10
Advanced heart failure patients supported with ambulatory inotropic therapy: What defines success of therapy?
Christopher S.GrubbMDaLauren K.TrubyMDbVeli K.TopkaraMDaMichael S.BohnenMD, PhDaMelanaYuzefpolskayaMDaErsilia M.DeFilippisMDaAudreyKleetNPaShunichiNakagawaMDaJennifer H.HaytheMDaKellyAxsomMDaPaoloColomboMDaKojiTakedaMD, PhDcNirUrielMD, MScaGabrielSayerMDaHasanGaranMDaYoshifumiNakaMD, PhDcMaryjaneFarrMD, MSca
doi : 10.1016/j.ahj.2021.05.001
Volume 239, September 2021, Pages 11-18
Depressive hypertension: A proposed human endotype of brain/gut microbiome dysbiosis
Bruce R.StevensPhDabc#Carl J.PepineMDd#Elaine M.RichardsPhDa#SeungbumKimPhDa#Mohan K.RaizadaPhDa#
doi : 10.1016/j.ahj.2021.05.002
Volume 239, September 2021, Pages 27-37
The impact of a population-based prevention program on cardiovascular events: Findings from the heart of new Ulm project
Abbey C.SidebottomMPH, PhDaMichael D.MiedemaMD, MPHbcGretchenBensonBAbMarcVacquierMSaJeffrey J.VanWormerPhDdArthurSillahMPH, PhDeRebeccaLindbergMPHbJackie L.BoucherMSfSteven M.BradleyMD, MPHbc
doi : 10.1016/j.ahj.2021.04.010
Volume 239, September 2021, Pages 38-51
Sarcopenia in cardiac surgery: Dual X-ray absorptiometry study from the McGill frailty registry
AayushiJoshiMScabRitaManciniMScabStephanProbstMDcGadAbikhzerMDcYvesLangloisMDdJean-FrancoisMorinMDdLawrence GRudskiMDeJonathanAfilaloMD, MSc, FACC, FRCPCabe
doi : 10.1016/j.ahj.2021.04.008
Volume 239, September 2021, Pages 52-58
Estimating the real-world performance of the PROMISE minimal-risk tool
MGNannaMD, MHSaTYWangMD, MHSaKChiswellPhDaJLSunMSaSVemulapalliMDaUHoffmannMD, MPHbMRPatelMDaJEUdelsonMDcCBFordyceMD, MHS, MScdPSDouglasMDa
doi : 10.1016/j.ahj.2021.05.016
Volume 239, September 2021, Pages 100-109
Early diuretic strategies and the association with In-hospital and Post-discharge outcomes in acute heart failure
MaratFudimMD, MHSabToiSpatesMDbJie-LenaSunMSaVeraprapasKittipibulMDcJeffrey M.TestaniMDdRandall C.StarlingMDeW.H. WilsonTangMDeAdrian F.HernandezMDabG. MichaelFelkerMD, MHSabChristopher M.O'ConnorMDfRobert J.MentzMDab
doi : 10.1016/j.ahj.2021.05.011
Volume 239, September 2021, Pages 110-119
Pre-operative atrial fibrillation and early right ventricular failure after left ventricular assist device implantation: a systematic review and meta-analysis
VeraprapasKittipibulMDaVanessaBlumerMDbGabriel A.HernandezMDcMaratFudimMD, MHSbRobertFlowersMDaSandraChaparroMDdRichaAgarwalMDb
doi : 10.1016/j.ahj.2021.05.009
Volume 239, September 2021, Pages 120-128
Simplifying the ISCHEMIA trial algorithm for clinical practice: Identifying left main coronary artery disease using coronary artery calcium scans
Joel E.MoneyMDabJoseph B.MuhlesteinMDabSteveMasonPA-CaTami L.BairaKirk U.KnowltonMDabBenjamin D.HornePhD, MStat, MPHacJeffrey L.AndersonMDab
doi : 10.1016/j.ahj.2021.05.013
Volume 239, September 2021, Pages 129-134
The association of healthcare disparities and patient-specific factors on clinical outcomes in peripheral artery disease
Dennis I.NarcisseMD, MSaCassie B.FordPhDbE. HopeWeisslerMDcdSteven J.LippmannPhDbMichelle M.SmerekBSbMelissa A.GreinerMSbN. ChantelleHardyMPHbBenjaminO'BrienBSbR. CaseySullivanMDeAdam J.BrockMDfChandlerLongMDdLesley H.CurtisPhDbcManesh R.PatelMDacW. SchuylerJonesMDac
doi : 10.1016/j.ahj.2021.05.014
Volume 239, September 2021, Pages 135-146
Effect of once-weekly exenatide on hospitalization for acute coronary syndrome or coronary revascularization in patients with type 2 diabetes mellitus
Carlos E.BarberyMDaAnnaGiczewskaMSbJenniferWhiteMSbYuliyaLokhnyginaPhDbRobert JohnMentzMDabRury R.HolmanMB ChBcNehaPagidipatiMDabAdrian F.HernandezMDabW. SchuylerJonesMDab
doi : 10.1016/j.ahj.2021.03.013
Volume 239, September 2021, Pages 59-63
